Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin leads to higher haematological adverse event: Grade 3/4 anaemia compared with tri‐weekly paclitaxel plus carboplatin (high certainty).
1 finding from 1 review
- Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes onlyRR 1.57 [1.12, 2.2]4 studies · 3639 participantsHigh